Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
CADILAHC On Other Exchanges
Symbol
Exchange
CADILAHC is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

cadila healthcare ltd (CADILAHC) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CADILA HEALTHCARE LTD (CADILAHC)

Related News

No related news articles were found.

cadila healthcare ltd (CADILAHC) Related Businessweek News

No Related Businessweek News Found

cadila healthcare ltd (CADILAHC) Details

Cadila Healthcare Limited discovers, develops, manufactures, and markets a range of healthcare products worldwide. It provides its products in various forms, including formulations, injectable, aerosols, ointments, vaccines, biologics, active pharmaceutical ingredients, etc. The company offers products in the areas of cardiovascular, gastro intestinal, respiratory, women’s healthcare, pain management, CNS, anti-infective, oncology, neuroscience, dermatology, nephrology, and chronic/lifestyle primarily under the Aten, Ocid, Deriphyllin, Pantodac, Atorva, Nucoxia, and Mifegest brands. It also provides consumer healthcare and wellness products, such as Sugar Free Gold, a sweetener; Sugar Free Natura, a sucralose based sugar substitute; Sugar Free D’lite, a healthy drink; Nutralite, a cholesterol-free table spread; and Actilife, a nutritional milk additive for adults, as well as skincare products comprising scrubs, peel-off, face wash, and soaps under its Everyuth and Dermacare brands. In addition, the company researches and develops a pipeline of 19 biologics comprising 17 biosimilars and 2 novel biological products; new drugs in cardio-metabolic, inflammation, pain, and oncology therapeutic areas; novel drug delivery systems; molecules for DMF filing and NPD molecules; and generic products, as well as solid orals, pulmonary, parenterals, suppository, topical, and oncology products. Further, it provides animal healthcare products comprising drugs, feed supplements, and vaccines for livestock, companion animals, and poultry. Additionally, the company develops vaccines that are designed to address infectious diseases, including next-generation influenza, measles-mumps-rubella-varicella, typhoid, DPT-HiB, hepatitis-B, hepatitis-A, hepatitis-E, Japanese encephalitis, and HPV. It has strategic out-licensing deal with Abbott Laboratories for the commercial supply of products. The company was founded in 1952 and is headquartered in Ahmedabad, India.

Founded in 1952

cadila healthcare ltd (CADILAHC) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

cadila healthcare ltd (CADILAHC) Key Developments

Cadila Healthcare Is Reported To Acquire Injectables Business Of Claris

Cadila Healthcare Limited (BSE:532321) has emerged as the front runner to acquire the generic sterile injectables business of Claris Lifesciences Limited (BSE:533288). Both Cadila and Claris are currently engaged in last-minute due diligence negotiations involving tax and other financial matters, said sources aware of the talks. Cadila is likely to pay a hefty premium, valuing the company at INR 31 billion to INR 34 billion. A formal announcement is expected early June 2015 provided there are no last-minute delays or glitches. The Cadila Healthcare spokesperson told Economic Times that as a matter of policy, the company does not comment on market speculation and a Claris spokesperson, however, denied any such development. Following the report, stock of Claris rallied as much as 17.79% in intraday trade on May 21, 2015.

Cadila Healthcare Limited Announces Audited Consolidated and Company Earnings Results for the Fourth Quarter and Year Ended Mach 31, 2015

Cadila Healthcare Limited announced audited consolidated and company earnings results for the fourth quarter and year ended Mach 31, 2015. For the quarter, on consolidated basis, the company reported net sales of INR 22,471.2 million against INR 19,163.3 million a year ago. Total income from operations (net) was INR 22,471.2 million against INR 19,685.0 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 4,203.3 million against INR 3,057.7 million a year ago. Profit from ordinary activities before tax was INR 4,258.2 million against INR 2,811.8 million a year ago. Net profit from ordinary activities after tax was INR 3,550.7 million or INR 17.11 per basic and diluted share before and after extraordinary items against INR 2,464.2 million or INR 11.68 per basic and diluted share before and after extraordinary items a year ago. For the year, on consolidated basis, the company reported net sales of INR 84,971.2 million against INR 70,600.7 million a year ago. Total income from operations (net) was INR 86,513.4 million against INR 72,240.3 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 14,684.6 million against INR 9,989.1 million a year ago. Profit from ordinary activities before tax was INR 14,455.3 million against INR 9,422.4 million a year ago. Net profit from ordinary activities after tax was INR 11,861.1 million or INR 56.20 per basic and diluted share before and after extraordinary items against INR 8,362.3 million or INR 38.25 per basic and diluted share before and after extraordinary items a year ago. Consolidated CapEx for the year was INR 3.8 billion. Return on net worth increased to 30.1% from 25.6% last year, while the return on capital employed increased to 18.3% from 14.6% last year. Consolidated debt at a gross levels stood at INR 26.5 billion, and debt net of cash stood at INR 19.8 billion. The company net debt equity ratio improved to 0.47 from 0.63 last year For the quarter, on company basis, the company reported net sales of INR 13,375.6 million against INR 9,904.2 million a year ago. Total income from operations (net) was INR 14,539.5 million against INR 11,015.4 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 4,075.7 million against INR 2,427.0 million a year ago. Profit from ordinary activities before tax was INR 4,086.1 million against INR 2,530.4 million a year ago. Net profit from ordinary activities after tax was INR 3,470.6 million or INR 16.95 per basic and diluted share before and after extraordinary items against INR 2,166.8 million or INR 10.58 per basic and diluted share before and after extraordinary items a year ago. For the year, on company basis, the company reported net sales of INR 46,860.9 million against INR 35,245.3 million a year ago. Total income from operations (net) was INR 52,844.3 million against INR 40,421.1 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 13,222.6 million against INR 6,795.9 million a year ago. Profit from ordinary activities before tax was INR 14,646.3 million against INR 9,456.7 million a year ago. Net profit from ordinary activities after tax was INR 12,711.2 million or INR 62.08 per basic and diluted share before and after extraordinary items against INR 9,035.9 million or INR 44.13 per basic and diluted share before and after extraordinary items a year ago.

Cadila Healthcare Ltd Recommends Dividend for the Year Ended March 31, 2015, payable on or after August 17, 2015

Cadila Healthcare Ltd. has informed that the Board of Directors of the company at its meeting held on May 15, 2015 recommended a dividend of INR 12 (@ 240%) per equity share on 204,748,520 equity shares of INR 5 for the year ended March 31, 2015. The Board of Directors has fixed August 3, 2015 to August 12, 2015 as the "Book Closure "dates for the purpose of determination of the members entitled for dividend. The dividend if declared by the members at the 20th Annual General Meeting to be held on August 12, 2015 will be paid to the members on or after August 17, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CDH:IN 1,839.25 INR +1.25

CADILAHC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cipla Ltd/India 631.55 INR +5.20
Glenmark Pharmaceuticals Ltd 1,019 INR -0.20
Piramal Enterprises Ltd 966.05 INR +10.50
Torrent Pharmaceuticals Ltd 1,322 INR +5.25
Wockhardt Ltd 1,426 INR +16.65
View Industry Companies
 

Industry Analysis

CADILAHC

Industry Average

Valuation CADILAHC Industry Range
Price/Earnings 32.2x
Price/Sales 4.3x
Price/Book 8.7x
Price/Cash Flow 25.7x
TEV/Sales 3.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CADILA HEALTHCARE LTD, please visit www.zyduscadila.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.